1,018 results on '"Rowe, Steven M."'
Search Results
2. Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells
3. Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
4. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
5. Transgenic ferret models define pulmonary ionocyte diversity and function
6. Human distal airways contain a multipotent secretory cell that can regenerate alveoli
7. Engineered tRNAs suppress nonsense mutations in cells and in vivo
8. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
9. Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
10. Potential systemic effects of acquired CFTR dysfunction in COPD
11. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
12. SNSP113 (PAAG) improves mucociliary transport and lung pathology in the Scnn1b-Tg murine model of CF lung disease
13. Red ginseng aqueous extract improves mucociliary transport dysfunction and histopathology in CF rat airways
14. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
15. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
16. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI
17. Lessons from other fields of medicine, Part 2: Cystic fibrosis
18. Metachrony drives effective mucociliary transport via a calcium-dependent mechanism
19. Pulmonary Fibrosis Ferret Model Demonstrates Sustained Fibrosis, Restrictive Physiology, and Aberrant Repair
20. Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D
21. Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferrets
22. Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.
23. A high‐resolution 3D atlas of the spectrum of tuberculous and COVID‐19 lung lesions
24. Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells
25. Targeting the Underlying Defect in CFTR with Small Molecule Compounds
26. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
27. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
28. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study
29. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation
30. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
31. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
32. Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data
33. Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis
34. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
35. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
36. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients
37. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
38. Korean Red Ginseng aqueous extract improves markers of mucociliary clearance by stimulating chloride secretion
39. Hypoxia‐induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis.
40. Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia.
41. Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis
42. Pharmacological approaches for targeting cystic fibrosis nonsense mutations
43. The future of cystic fibrosis care: a global perspective
44. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
45. Pulmonary Fibrosis Stakeholder Summit: A Joint National Heart, Lung, and Blood Institute, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report
46. Hypoxia‐induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis
47. Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study
48. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion
49. Geometry-Dependent Spectroscopic Contrast in Deep Tissues
50. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.